Muscle Loss on GLP-1s: What the DEXA Data Shows and How to Protect Lean Mass

Any large weight loss — surgical, dietary, or pharmacological — takes lean tissue along with fat, and GLP-1-class drugs are no exception. In body-composition substudies of the major trials, roughly 25% to 40% of total weight lost was lean mass, with tirzepatide's SURMOUNT-1 substudy near the lower-middle of that band and fat mass falling around three times faster than lean mass. The headline is easily overstated in both directions: this is not muscle "melting away," and it is not nothing.

Why it matters more at the finish than the start

Lean mass anchors resting metabolic rate, physical function, and — critically — what your body composition looks like at goal weight and through maintenance. Losing 25% of a 50-pound reduction as lean tissue is a materially different outcome than losing 15% of it, especially for adults over 50, for whom sarcopenia risk compounds, and for anyone who eventually tapers the drug: regained weight after GLP-1 discontinuation returns disproportionately as fat, so lean mass protected during the loss phase is the asset you keep. This is one of the quiet arguments for treating the loss phase as a body-composition project, not a scale project.

The two interventions with actual evidence

Nothing exotic wins here. Protein: appetite suppression makes under-eating protein nearly automatic, and the practical target used in medical weight management is roughly 1.2–1.6 grams per kilogram of body weight daily (higher end for older adults), front-loaded early in the day when the drug most blunts intake. Resistance training: two to three sessions weekly of progressive load is the single best-evidenced lever for preserving lean mass during caloric deficit, and it outperforms cardio for this specific purpose. Everything else — leucine timing, HMB, creatine as an adjunct — is supporting cast with thinner evidence. The pharmaceutical industry agrees this is the frontier: multiple myostatin-pathway and other muscle-preserving agents are in trials specifically to pair with incretin therapy, but none is approved, and the 2026 answer remains protein plus progressive resistance.

The practical program

Weigh weekly but measure monthly (photos, waist, strength benchmarks); ask your prescriber whether a DEXA baseline is worth it if you are starting lean or older; hit the protein floor daily before optimizing anything else; and lift twice weekly minimum with progression. If strength is falling faster than a few percent while the scale drops, that is a titration-pace and nutrition conversation with your clinician, not a reason to abandon effective therapy. Related: what happens when you stop, where lean-mass preservation pays its dividend.